Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 9, Issue 3, 2004, Pages 185-192

  Bae, Jang Ho ^a   Bassenge, Eberhard ^b   Kim, Ki Young ^a   Synn, Yi Chul ^a   Park, Ki Rack ^a   Schwemmer, Michael ^b  

^a Konyang University College of Medicine   (South Korea)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Coronary artery disease; Endothelial function; Restenosis; Statin

Indexed keywords

ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BLOOD VESSEL REACTIVITY; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; ENDOTHELIUM CELL; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HUMAN CELL; INTERNAL CAROTID ARTERY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; SIDE EFFECT; ST SEGMENT ELEVATION; STROKE;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CAROTID ARTERIES; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; STENTS;

EID: 4944252423     PISSN: 10742484     EISSN: None     Source Type: Journal    
DOI: 10.1177/107424840400900306     Document Type: Article

References (25)

1. Celermajer DS, Sorensen KE, Bull C, et al. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24(6):1468-1474, 1994
2. Davis PH, Dawson JD, Riley WA, et al. Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation 104(23):2815-2919, 2001
3. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 104(2):191-196, 2001
4. Heitzer T, Schlinzig T, Krohn K, et al. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with CAD. Circulation 104(22):2673-2678, 2001
5. Liao JK. Beyond lipid lowering: The role of statins in vascular protection. Int J Cardiol 86(1):5-18, 2002
6. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with CAD. N Engl J Med 332(8):481-487, 1995
7. Masumoto A, Hirooka Y, Hironaga K, et al. Effect of pravastatin on endothelial function in patients with CAD (cholesterol-independent effect of pravastatin). Am J Cardiol 88(11):1291-1294, 2001
8. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): A prospective, randomised, double-blind trial. Lancet 357(9256):577-581, 2001
9. Walter DH, Schachinger V, Elsner M, et al. Effect of statin therapy on restenosis after coronary stent implantation. Am J Cardiol 85(8):962-968, 2000
10. Walter DH, Schachinger V, Elsner M, et al. Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the Pl(A2)allele of the platelet glycoprotein IIIa gene. Eur Heart J 22(7):587-595, 2001
11. Bae JH, Bassenge E, Kim KB, et al. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis 155(2):517-523, 2001
12. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 81(3):333-335, 1998
13. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: A randomized controlled trial. JAMA 285(13):1711-1718, 2001
14. Mulder HJ, Bal ET, Jukema JW, et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol 86(7):742-746, 2000
15. John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: A randomized, placebo-controlled, double-blind study. Circulation 98(3):211-216, 1998
16. Vita JA, Yeung AC, Winniford M, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with CAD. Circulation 102(8):846-851, 2000
17. Kaesemeyer WH, Caldwell RB, Huang J, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33(1):234-241, 1999
18. Asberg A, Hartmann A, Fjeldsa E, et al. Atorvastatin improves endothelial function in renal-transplant recipients. Nephrol Dial Transplant 16(9):1920-1924, 2001
19. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101(12):2711-2719, 1998
20. Jones SP, Teshima Y, Akao M, et al. Simvastatin attenuates oxidant-induced mitochondrial dysfunction in cardiac myocytes. Circ Res 93(8):697-699, 2003
21. Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95(1):76-82, 1997
22. Singh TP, Groehn H, Kazmers A. Vascular function and carotid intimal-medial thickness in children with insulin-dependent diabetes mellitus. J Am Coll Cardiol 41(4):661-665, 2003
23. Serruys PW, Foley DP, Jackson G, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. Eur Heart J 20(1):58-69, 1999
24. von Haehling S, Anker SD, Bassenge E. Statins and the role of nitric oxide in chronic heart failure. Heart Fail Rev 8(1):99-106, 2003
25. Erl W, Hristov M, Neureuter M, et al. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis 169(2):251-258, 2003